Search Results for "miller"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for miller. Results 1 to 8 of 8 total matches.

Diazoxide Choline (Vykat XR) for Prader-Willi Syndrome-Associated Hyperphagia (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 28, 2025  (Issue 1727)
. Genes (Basel) 2020; 11:450. 3. JL Miller et al. Diazoxide choline extended-release tablet in people ...
The FDA has approved diazoxide choline extended-release tablets (Vykat XR – Soleno Therapeutics) for treatment of hyperphagia in patients ≥4 years old with Prader-Willi syndrome. Diazoxide choline is the first drug to be approved in the US for this indication. Diazoxide oral suspension (Proglycem) has been available for years for management of symptomatic hypoglycemia.
Med Lett Drugs Ther. 2025 Apr 28;67(1727):e72-3   doi:10.58347/tml.2025.1727e |  Show IntroductionHide Introduction

Tofersen (Qalsody) for ALS

   
The Medical Letter on Drugs and Therapeutics • Jul 24, 2023  (Issue 1681)
from those with placebo. Serious neurologic adverse events have occurred. 1. TM Miller et al. Trial ...
Tofersen (Qalsody – Biogen), an intrathecally administered antisense oligonucleotide, has received accelerated approval from the FDA for treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. About 2% of patients with ALS have mutations in the SOD1 gene. Tofersen is the first drug to be approved in the US that targets a genetic cause of ALS. Accelerated approval of the drug was based on the surrogate endpoint of a reduction in plasma neurofilament light chain, which is considered likely to predict clinical...
Med Lett Drugs Ther. 2023 Jul 24;65(1681):113-4   doi:10.58347/tml.2023.1681a |  Show IntroductionHide Introduction

In Brief: New Warning for the RSV Vaccines Arexvy and Abrysvo

   
The Medical Letter on Drugs and Therapeutics • Feb 17, 2025  (Issue 1722)
after vaccination with Arexvy and one case each of GBS and Miller Fisher syndrome (a variant of GBS ...
The FDA has required a new warning in the labels of the recombinant respiratory syncytial virus (RSV) vaccines Arexvy (GSK) and Abrysvo (Pfizer) about an increased risk of Guillain-Barré syndrome (GBS) within 42 days of administration of either vaccine. Both vaccines are FDA-approved to prevent lower respiratory tract disease (LRTD) caused by RSV in adults.Abrysvo is also approved for use in pregnant women at 32-36 weeks' gestation to prevent RSV-associated LRTD in their infants from birth through 6 months of age.
Med Lett Drugs Ther. 2025 Feb 17;67(1722):31-2   doi:10.58347/tml.2025.1722d |  Show IntroductionHide Introduction

Relyvrio for ALS

   
The Medical Letter on Drugs and Therapeutics • Nov 28, 2022  (Issue 1664)
J Med 2017; 377:162. 4. RG Miller et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor ...
The FDA has approved Relyvrio (Amylyx), a fixed-dose combination of sodium phenylbutyrate and taurursodiol, for treatment of amyotrophic lateral sclerosis (ALS). Sodium phenylbutyrate (Buphenyl, and others) has been available by prescription for years for treatment of urea cycle disorders. Taurursodiol (tauroursodeoxycholic acid), a derivative of ursodiol, is an over-the-counter bile acid supplement claimed to have neuroprotective benefits. Relyvrio is the third drug to be approved in the US for treatment of ALS; riluzole (Rilutek, and others) and edaravone (Radicava, Radicava...
Med Lett Drugs Ther. 2022 Nov 28;64(1664):190-1 |  Show IntroductionHide Introduction

Drugs for Postmenopausal Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • Jul 08, 2024  (Issue 1706)
Lett Drugs Ther 2017; 59:97. 32. PD Miller et al. Bone mineral density response rates are greater ...
Pharmacologic treatment is recommended for postmenopausal women who have bone density T-scores (standard deviations from normal mean values in the spine, femoral neck, total hip, or distal radius) of -2.5 or below, T-scores between -1.0 and -2.5 with a history of fragility (low-trauma) fracture of the hip or spine, or T-scores between -1.0 and -2.5 with a FRAX 10-year probability of ≥3% for hip fracture or ≥20% for major osteoporotic fracture.
Med Lett Drugs Ther. 2024 Jul 8;66(1706):105-12   doi:10.58347/tml.2024.1706a |  Show IntroductionHide Introduction

Two Vaccines (Arexvy and Abrysvo) for Prevention of RSV Disease

   
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023  (Issue 1686)
, and one case each of GBS and Miller Fisher syndrome (a variant of GBS) 7 and 8 days, respectively, after ...
Two recombinant vaccines, Arexvy (GSK) and Abrysvo (Pfizer), have been approved by the FDA for prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults ≥60 years old. They are the first RSV vaccines to be approved in the US. Abrysvo is also approved for use in pregnant women at 32-36 weeks' gestation to prevent LRTD caused by RSV in their infants from birth through 6 months of age.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):155-6   doi:10.58347/tml.2023.1686a |  Show IntroductionHide Introduction

Insect Repellents

   
The Medical Letter on Drugs and Therapeutics • Jul 12, 2021  (Issue 1628)
Miller et al. Tick bite protection with permethrin-treated summer-weight clothing. J Med Entomol 2011 ...
The Centers for Disease Control and Prevention (CDC) and the Environmental Protection Agency (EPA) recommend using insect repellents to prevent infections transmitted by mosquitoes and ticks. Insect repellents applied to exposed skin should be used in conjunction with other preventive measures such as wearing pants and long-sleeved shirts and avoiding outdoor activities during peak mosquito-biting times. Mosquitoes can transmit diseasecausing pathogens, including Zika, chikungunya, dengue, West Nile, eastern equine encephalitis, and yellow fever viruses, and the malaria parasite....
Med Lett Drugs Ther. 2021 Jul 12;63(1628):109-12 |  Show IntroductionHide Introduction

Opioids for Pain

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022  (Issue 1665)
. Cochrane Database Syst Rev 2014 Dec; 2014 (12):CD009281. 6. M Miller et al. Prescription opioid duration ...
A new CDC guideline for prescribing opioids for pain recently became available. Nonopioid drugs for pain were reviewed in a previous issue.
Med Lett Drugs Ther. 2022 Dec 12;64(1665):193-200 |  Show IntroductionHide Introduction